查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
鈣通道阻斷劑市場 - 2023-2031年全球行業分析、規模、佔有率、成長、趨勢和預測
市場調查報告書
商品編碼
1301438

鈣通道阻斷劑市場 - 2023-2031年全球行業分析、規模、佔有率、成長、趨勢和預測

Calcium Channel Blockers Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日期: | 出版商: Transparency Market Research | 英文 185 Pages | 商品交期: 2-10個工作天內

價格

鈣通道阻斷劑市場- 報告範圍

TMR關於全球鈣通道阻斷劑市場的報告研究了過去以及當前的成長趨勢和機會，以便在2023年至2031年的預測期間獲得對市場指標的寶貴見解。報告提供了2017-2031年期間全球鈣通道阻斷劑市場的收入，考慮到2023年為基準年，2031年為預測年。報告還提供了2023年至2031年全球鈣通道阻斷劑市場的複合年成長率（CAGR %）。

該報告是在廣泛的研究後編寫的。一級研究涉及大部分的研究工作，其中分析師與關鍵意見領袖、行業領袖和意見製造者進行了訪談。二級研究包括參考主要參與者的產品資料、年度報告、新聞稿和相關文件，以了解鈣通道阻斷劑市場。

報告深入研究了全球鈣通道阻斷劑市場的競爭格局。在全球鈣通道阻斷劑市場運作的主要參與者已被確定，其中每一個都在各種屬性方面進行了分析。公司概況、財務狀況、近期發展和SWOT是本報告對全球鈣通道阻斷劑市場參與者的屬性描述。

目錄

第一章：前言

  • 市場定義和範圍
  • 市場細分
  • 主要研究目標
  • 研究重點

第二章：假設和研究方法

第三章：執行摘要：全球市場

第四章：市場概述

  • 簡介
    • 定義
    • 行業演變/發展
  • 概述
  • 市場動態
    • 驅動力
    • 限制因素
    • 機會
  • 2017-2031年全球市場分析和預測
    • 市場收入預測

第5章：關鍵洞察力

  • 全球及主要國家的疾病流行率和發病率
  • 主要產品/品牌分析
  • 管線分析
  • COVID-19大流行對行業的影響

第六章：全球市場分析和預測：按藥物類別分類

  • 介紹和定義
  • 主要研究結果/發展情況
  • 市場價值預測：按藥物類別，2017-2031年
    • 苯基烷基胺
    • 苯妥英
    • 二氫吡啶
      • 第一代
      • 第二代
      • 第三代
  • 市場吸引力分析：按藥物類別

第7章：全球市場分析和預測：按應用分類

  • 介紹和定義
  • 主要研究結果/發展情況
  • 市場價值預測：按應用分類，2017-2031年
    • 高血壓
    • 心絞痛
    • 心律失常
    • 肥厚型心肌病
    • 其他（雷諾氏病，等）
  • 市場吸引力分析：按應用分類

第八章：全球市場分析與預測：按給藥途徑分類

  • 介紹和定義
  • 主要研究結果/發展情況
  • 市場價值預測：按給藥途徑，2017-2031年
    • 口服
    • 腸外
  • 市場吸引力分析：按給藥途徑分類

第九章：全球市場分析和預測：按配銷通路分類

  • 介紹和定義
  • 主要研究結果/發展情況
  • 市場價值預測：按配銷通路分類，2017-2031年
    • 醫院藥房
    • 零售藥店
    • 網上藥店
  • 市場吸引力分析：按配銷通路分類

第十章：全球市場分析與預測：按地區分類

  • 主要研究結果
  • 市場價值預測：按地區
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 市場吸引力分析：按地區

第11章：北美洲市場分析與預測

  • 簡介
    • 主要研究結果
  • 市場價值預測：按藥物類別，2017-2031年
    • 苯基烷基胺
    • 苯硫酚類
    • 二氫吡啶
      • 第一代
      • 第二代
      • 第三代
  • 市場價值預測：按應用分類，2017-2031年
    • 高血壓
    • 心絞痛
    • 心律失常
    • 肥厚型心肌病
    • 其他（雷諾氏病等）。
  • 市場價值預測：按給藥途徑，2017-2031年
    • 口服
    • 腸外
  • 市場價值預測：按配銷通路，2017-2031年
    • 醫院藥房
    • 零售藥店
    • 網上藥店
  • 市場價值預測：按國家分類，2017-2031年
    • 美國
    • 加拿大
  • 市場吸引力分析
    • 按藥物類別
    • 按應用分類
    • 按給藥途徑分類
    • 按銷售管道分類
    • 按國家分類

第12章：歐洲市場分析和預測

  • 簡介
    • 主要發現
  • 市場價值預測：按藥物類別，2017-2031年
    • 苯基烷基胺
    • 苯硫酚類
    • 二氫吡啶
      • 第一代
      • 第二代
      • 第三代
  • 市場價值預測：按應用分類，2017-2031年
    • 高血壓
    • 心絞痛
    • 心律失常
    • 肥厚型心肌病
    • 其他（雷諾氏病等）。
  • 市場價值預測：按給藥途徑，2017-2031年
    • 口服
    • 腸外
  • 市場價值預測：按配銷通路，2017-2031年
    • 醫院藥房
    • 零售藥店
    • 網上藥店
  • 市場價值預測：按國家/次區域分類，2017-2031年
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 市場吸引力分析
    • 按藥物類別
    • 按應用分類
    • 按給藥途徑分類
    • 按配銷通路
    • 按國家/次區域分類

第13章：亞太地區市場分析和預測

  • 簡介
    • 主要發現
  • 市場價值預測：按藥物類別，2017-2031年
    • 苯基烷基胺
    • 苯硫酚類
    • 二氫吡啶
      • 第一代
      • 第二代
      • 第三代
  • 市場價值預測：按應用分類，2017-2031年
    • 高血壓
    • 心絞痛
    • 心律失常
    • 肥厚型心肌病
    • 其他（雷諾氏病等）。
  • 市場價值預測：按給藥途徑，2017-2031年
    • 口服
    • 腸外
  • 市場價值預測：按配銷通路，2017-2031年
    • 醫院藥房
    • 零售藥店
    • 網上藥店
  • 市場價值預測：按國家/次區域分類，2017-2031年
    • 中國
    • 日本
    • 印度
    • 澳大利亞和新西蘭
    • 亞太其他地區
  • 市場吸引力分析
    • 按藥物類別
    • 按應用分類
    • 按給藥途徑
    • 按配銷通路
    • 按國家/次區域分類

第十四章：拉丁美洲市場分析與預測

  • 簡介
    • 主要發現
  • 市場價值預測：按藥物類別，2017-2031年
    • 苯基烷基胺
    • 苯硫酚類
    • 二氫吡啶
      • 第一代
      • 第二代
      • 第三代
  • 市場價值預測：按應用分類，2017-2031年
    • 高血壓
    • 心絞痛
    • 心律失常
    • 肥厚型心肌病
    • 其他（雷諾氏病等）。
  • 市場價值預測：按給藥途徑，2017-2031年
    • 口服
    • 腸外
  • 市場價值預測：按配銷通路，2017-2031年
    • 醫院藥房
    • 零售藥店
    • 網上藥店
  • 市場價值預測：按國家/次區域分類，2017-2031年
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區
  • 市場吸引力分析
    • 按藥物類別
    • 按應用分類
    • 按給藥途徑分類
    • 按配銷通路
    • 按國家/次區域分類

第15章：中東和非洲市場分析和預測

  • 簡介
    • 主要發現
  • 市場價值預測：按藥物類別，2017-2031年
    • 苯基烷基胺
    • 苯妥英
    • 二氫吡啶
      • 第一代
      • 第二代
      • 第三代
  • 市場價值預測：按應用分類，2017-2031年
    • 高血壓
    • 心絞痛
    • 心律失常
    • 肥厚型心肌病
    • 其他（雷諾氏病等）。
  • 市場價值預測：按給藥途徑，2017-2031年
    • 口服
    • 腸外
  • 市場價值預測：按配銷通路，2017-2031年
    • 醫院藥房
    • 零售藥店
    • 網上藥店
  • 市場價值預測：按國家/次區域分類，2017-2031年
    • 海灣合作理事會國家
    • 南非
    • 中東和非洲其他地區
  • 市場吸引力分析
    • 按藥物類別
    • 按應用分類
    • 按給藥途徑分類
    • 按配銷通路
    • 按國家/次區域分類

第16章：競爭格局

  • 市場參與者- 競爭矩陣（按公司的層級和規模分類）
  • 市場佔有率分析：按公司分類，2022年
  • 公司簡介
    • Pfizer, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Bausch Health Company, Inc.
    • Novartis AG
    • AstraZeneca
    • Merck & Co. Inc.
    • GSK plc
    • Bayer AG
    • Sun Pharmaceutical Industries Ltd.
    • Daiichi Sankyo Company, Limited
Product Code: TMRGL35687

Calcium Channel Blockers Market - Scope of Report

TMR's report on the global Calcium Channel Blockers market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Calcium Channel Blockers market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Calcium Channel Blockers market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the Calcium Channel Blockers market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Calcium Channel Blockers market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Calcium Channel Blockers market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Calcium Channel Blockers market.

The report delves into the competitive landscape of the global Calcium Channel Blockers market. Key players operating in the global Calcium Channel Blockers market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Calcium Channel Blockers market profiled in this report.

Key Questions Answered in Global Calcium Channel Blockers Market Report:

  • What is the sales/revenue generated by Calcium Channel Blockers across all regions during the forecast period?
  • What are the opportunities in the global Calcium Channel Blockers market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Calcium Channel Blockers Market - Research Objectives and Research Approach

The comprehensive report on the global Calcium Channel Blockers market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Calcium Channel Blockers market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Calcium Channel Blockers market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Calcium Channel Blockers Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Calcium Channel Blockers Market Analysis and Forecast, 2017-2031
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

  • 5.1. Disease Prevalence & Incidence Rate globally with key countries
  • 5.2. Key product/brand Analysis
  • 5.3. Pipeline Analysis
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Calcium Channel Blockers Market Analysis and Forecast, by Drug Class

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast, by Drug Class, 2017-2031
    • 6.3.1. Phenylalkylamine
    • 6.3.2. Benzothizepine
    • 6.3.3. Dihydropyridine
      • 6.3.3.1. 1st Generation
      • 6.3.3.2. 2nd Generation
      • 6.3.3.3. 3rd Generation
  • 6.4. Market Attractiveness Analysis, by Drug Class

7. Global Calcium Channel Blockers Market Analysis and Forecast, by Application

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast, by Application, 2017-2031
    • 7.3.1. Hypertension
    • 7.3.2. Angina
    • 7.3.3. Arrhythmia
    • 7.3.4. Hypertrophic Cardiomyopathy
    • 7.3.5. Others (Raynaud's disease, etc.)
  • 7.4. Market Attractiveness Analysis, by Application

8. Global Calcium Channel Blockers Market Analysis and Forecast, by Route of Administration

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 8.3.1. Oral
    • 8.3.2. Parenteral
  • 8.4. Market Attractiveness Analysis, by Route of Administration

9. Global Calcium Channel Blockers Market Analysis and Forecast, by Distribution Channel

  • 9.1. Introduction & Definition
  • 9.2. Key Findings / Developments
  • 9.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Retail Pharmacies
    • 9.3.3. Online Pharmacies
  • 9.4. Market Attractiveness Analysis, by Distribution Channel

10. Global Calcium Channel Blockers Market Analysis and Forecast, by Region

  • 10.1. Key Findings
  • 10.2. Market Value Forecast, by Region
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Market Attractiveness Analysis, by Region

11. North America Calcium Channel Blockers Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Drug Class, 2017-2031
    • 11.2.1. Phenylalkylamine
    • 11.2.2. Benzothizepine
    • 11.2.3. Dihydropyridine
      • 11.2.3.1. 1st Generation
      • 11.2.3.2. 2nd Generation
      • 11.2.3.3. 3rd Generation
  • 11.3. Market Value Forecast, by Application, 2017-2031
    • 11.3.1. Hypertension
    • 11.3.2. Angina
    • 11.3.3. Arrhythmia
    • 11.3.4. Hypertrophic Cardiomyopathy
    • 11.3.5. Others (Raynaud's disease, etc.)
  • 11.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 11.4.1. Oral
    • 11.4.2. Parenteral
  • 11.5. Market Value Forecast, by Distribution Channel, 2017-2031
    • 11.5.1. Hospital Pharmacies
    • 11.5.2. Retail Pharmacies
    • 11.5.3. Online Pharmacies
  • 11.6. Market Value Forecast, by Country, 2017-2031
    • 11.6.1. U.S.
    • 11.6.2. Canada
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Drug Class
    • 11.7.2. By Application
    • 11.7.3. By Route of Administration
    • 11.7.4. By Distribution Channel
    • 11.7.5. By Country

12. Europe Calcium Channel Blockers Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Drug Class, 2017-2031
    • 12.2.1. Phenylalkylamine
    • 12.2.2. Benzothizepine
    • 12.2.3. Dihydropyridine
      • 12.2.3.1. 1st Generation
      • 12.2.3.2. 2nd Generation
      • 12.2.3.3. 3rd Generation
  • 12.3. Market Value Forecast, by Application, 2017-2031
    • 12.3.1. Hypertension
    • 12.3.2. Angina
    • 12.3.3. Arrhythmia
    • 12.3.4. Hypertrophic Cardiomyopathy
    • 12.3.5. Others (Raynaud's disease, etc.)
  • 12.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 12.4.1. Oral
    • 12.4.2. Parenteral
  • 12.5. Market Value Forecast, by Distribution Channel, 2017-2031
    • 12.5.1. Hospital Pharmacies
    • 12.5.2. Retail Pharmacies
    • 12.5.3. Online Pharmacies
  • 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.6.1. Germany
    • 12.6.2. U.K.
    • 12.6.3. France
    • 12.6.4. Spain
    • 12.6.5. Italy
    • 12.6.6. Rest of Europe
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Drug Class
    • 12.7.2. By Application
    • 12.7.3. By Route of Administration
    • 12.7.4. By Distribution Channel
    • 12.7.5. By Country/Sub-region

13. Asia Pacific Calcium Channel Blockers Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Drug Class, 2017-2031
    • 13.2.1. Phenylalkylamine
    • 13.2.2. Benzothizepine
    • 13.2.3. Dihydropyridine
      • 13.2.3.1. 1st Generation
      • 13.2.3.2. 2nd Generation
      • 13.2.3.3. 3rd Generation
  • 13.3. Market Value Forecast, by Application, 2017-2031
    • 13.3.1. Hypertension
    • 13.3.2. Angina
    • 13.3.3. Arrhythmia
    • 13.3.4. Hypertrophic Cardiomyopathy
    • 13.3.5. Others (Raynaud's disease, etc.)
  • 13.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 13.4.1. Oral
    • 13.4.2. Parenteral
  • 13.5. Market Value Forecast, by Distribution Channel, 2017-2031
    • 13.5.1. Hospital Pharmacies
    • 13.5.2. Retail Pharmacies
    • 13.5.3. Online Pharmacies
  • 13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.6.1. China
    • 13.6.2. Japan
    • 13.6.3. India
    • 13.6.4. Australia & New Zealand
    • 13.6.5. Rest of Asia Pacific
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Drug Class
    • 13.7.2. By Application
    • 13.7.3. By Route of Administration
    • 13.7.4. By Distribution Channel
    • 13.7.5. By Country/Sub-region

14. Latin America Calcium Channel Blockers Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Drug Class, 2017-2031
    • 14.2.1. Phenylalkylamine
    • 14.2.2. Benzothizepine
    • 14.2.3. Dihydropyridine
      • 14.2.3.1. 1st Generation
      • 14.2.3.2. 2nd Generation
      • 14.2.3.3. 3rd Generation
  • 14.3. Market Value Forecast, by Application, 2017-2031
    • 14.3.1. Hypertension
    • 14.3.2. Angina
    • 14.3.3. Arrhythmia
    • 14.3.4. Hypertrophic Cardiomyopathy
    • 14.3.5. Others (Raynaud's disease, etc.)
  • 14.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 14.4.1. Oral
    • 14.4.2. Parenteral
  • 14.5. Market Value Forecast, by Distribution Channel, 2017-2031
    • 14.5.1. Hospital Pharmacies
    • 14.5.2. Retail Pharmacies
    • 14.5.3. Online Pharmacies
  • 14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.6.1. Brazil
    • 14.6.2. Mexico
    • 14.6.3. Rest of Latin America
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Drug Class
    • 14.7.2. By Application
    • 14.7.3. By Route of Administration
    • 14.7.4. By Distribution Channel
    • 14.7.5. By Country/Sub-region

15. Middle East & Africa Calcium Channel Blockers Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Drug Class, 2017-2031
    • 15.2.1. Phenylalkylamine
    • 15.2.2. Benzothizepine
    • 15.2.3. Dihydropyridine
      • 15.2.3.1. 1st Generation
      • 15.2.3.2. 2nd Generation
      • 15.2.3.3. 3rd Generation
  • 15.3. Market Value Forecast, by Application, 2017-2031
    • 15.3.1. Hypertension
    • 15.3.2. Angina
    • 15.3.3. Arrhythmia
    • 15.3.4. Hypertrophic Cardiomyopathy
    • 15.3.5. Others (Raynaud's disease, etc.)
  • 15.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 15.4.1. Oral
    • 15.4.2. Parenteral
  • 15.5. Market Value Forecast, by Distribution Channel, 2017-2031
    • 15.5.1. Hospital Pharmacies
    • 15.5.2. Retail Pharmacies
    • 15.5.3. Online Pharmacies
  • 15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 15.6.1. GCC Countries
    • 15.6.2. South Africa
    • 15.6.3. Rest of Middle East & Africa
  • 15.7. Market Attractiveness Analysis
    • 15.7.1. By Drug Class
    • 15.7.2. By Application
    • 15.7.3. By Route of Administration
    • 15.7.4. By Distribution Channel
    • 15.7.5. By Country/Sub-region

16. Competition Landscape

  • 16.1. Market Player - Competition Matrix (by tier and size of companies)
  • 16.2. Market Share Analysis, by Company, 2022
  • 16.3. Company Profiles
    • 16.3.1. Pfizer, Inc.
      • 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.1.2. Product Portfolio
      • 16.3.1.3. Financial Overview
      • 16.3.1.4. SWOT Analysis
      • 16.3.1.5. Strategic Overview
    • 16.3.2. Teva Pharmaceutical Industries Ltd.
      • 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.2.2. Product Portfolio
      • 16.3.2.3. Financial Overview
      • 16.3.2.4. SWOT Analysis
      • 16.3.2.5. Strategic Overview
    • 16.3.3. Bausch Health Company, Inc.
      • 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.3.2. Product Portfolio
      • 16.3.3.3. Financial Overview
      • 16.3.3.4. SWOT Analysis
      • 16.3.3.5. Strategic Overview
    • 16.3.4. Novartis AG
      • 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.4.2. Product Portfolio
      • 16.3.4.3. Financial Overview
      • 16.3.4.4. SWOT Analysis
      • 16.3.4.5. Strategic Overview
    • 16.3.5. AstraZeneca
      • 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.5.2. Product Portfolio
      • 16.3.5.3. Financial Overview
      • 16.3.5.4. SWOT Analysis
      • 16.3.5.5. Strategic Overview
    • 16.3.6. Merck & Co. Inc.
      • 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.6.2. Product Portfolio
      • 16.3.6.3. Financial Overview
      • 16.3.6.4. SWOT Analysis
      • 16.3.6.5. Strategic Overview
    • 16.3.7. GSK plc
      • 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.7.2. Product Portfolio
      • 16.3.7.3. Financial Overview
      • 16.3.7.4. SWOT Analysis
      • 16.3.7.5. Strategic Overview
    • 16.3.8. Bayer AG
      • 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.8.2. Product Portfolio
      • 16.3.8.3. Financial Overview
      • 16.3.8.4. SWOT Analysis
      • 16.3.8.5. Strategic Overview
    • 16.3.9. Sun Pharmaceutical Industries Ltd.
      • 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.9.2. Product Portfolio
      • 16.3.9.3. Financial Overview
      • 16.3.9.4. SWOT Analysis
      • 16.3.9.5. Strategic Overview
    • 16.3.10. Daiichi Sankyo Company, Limited
      • 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.10.2. Product Portfolio
      • 16.3.10.3. Financial Overview
      • 16.3.10.4. SWOT Analysis
      • 16.3.10.5. Strategic Overview

List of Tables

  • Table 01. Global Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 02. Global Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 03. Global Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 04. Global Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 05. Global Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 06. North America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 07. North America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 08. North America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 09. North America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 10. North America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 11. Europe Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 12. Europe Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 13. Europe Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 14. Europe Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 15. Europe Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 16. Asia Pacific Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 17. Asia Pacific Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 18. Asia Pacific Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 19. Asia Pacific Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 20. Asia Pacific Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 21. Latin America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 22. Latin America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 23. Latin America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 24. Latin America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 25. Latin America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 26. Middle East & Africa Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 27. Middle East & Africa Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 28. Middle East & Africa Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 29. Middle East & Africa Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 30. Middle East & Africa Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

List of Figures

  • Figure 01. Global Calcium Channel Blockers Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02. Global Calcium Channel Blockers Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 03. Global Calcium Channel Blockers Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 04. Global Calcium Channel Blockers Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 05. Global Calcium Channel Blockers Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 06. Global Calcium Channel Blockers Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 07. Global Calcium Channel Blockers Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 08. Global Calcium Channel Blockers Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 09. Global Calcium Channel Blockers Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 10. Global Calcium Channel Blockers Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 11. Global Calcium Channel Blockers Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 12. North America Calcium Channel Blockers Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 13. North America Calcium Channel Blockers Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 14. North America Calcium Channel Blockers Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 15. North America Calcium Channel Blockers Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 16. North America Calcium Channel Blockers Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 17. North America Calcium Channel Blockers Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 18. North America Calcium Channel Blockers Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 19. North America Calcium Channel Blockers Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 20. North America Calcium Channel Blockers Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 21. North America Calcium Channel Blockers Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 22. North America Calcium Channel Blockers Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 23. Europe Calcium Channel Blockers Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 24. Europe Calcium Channel Blockers Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 25. Europe Calcium Channel Blockers Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 26. Europe Calcium Channel Blockers Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 27. Europe Calcium Channel Blockers Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 28. Europe Calcium Channel Blockers Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 29. Europe Calcium Channel Blockers Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 30. Europe Calcium Channel Blockers Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 31. Europe Calcium Channel Blockers Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 32. Europe Calcium Channel Blockers Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 33. Europe Calcium Channel Blockers Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 34. Asia Pacific Calcium Channel Blockers Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 35. Asia Pacific Calcium Channel Blockers Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 36. Asia Pacific Calcium Channel Blockers Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 37. Asia Pacific Calcium Channel Blockers Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 38. Asia Pacific Calcium Channel Blockers Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 39. Asia Pacific Calcium Channel Blockers Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 40. Asia Pacific Calcium Channel Blockers Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 41. Asia Pacific Calcium Channel Blockers Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 42. Asia Pacific Calcium Channel Blockers Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 43. Asia Pacific Calcium Channel Blockers Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 44. Asia Pacific Calcium Channel Blockers Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 45. Latin America Calcium Channel Blockers Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 46. Latin America Calcium Channel Blockers Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 47. Latin America Calcium Channel Blockers Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 48. Latin America Calcium Channel Blockers Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 49. Latin America Calcium Channel Blockers Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 50. Latin America Calcium Channel Blockers Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 51. Latin America Calcium Channel Blockers Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 52. Latin America Calcium Channel Blockers Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 53. Latin America Calcium Channel Blockers Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 54. Latin America Calcium Channel Blockers Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 55. Latin America Calcium Channel Blockers Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 56. Middle East & Africa Calcium Channel Blockers Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 57. Middle East & Africa Calcium Channel Blockers Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 58. Middle East & Africa Calcium Channel Blockers Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 59. Middle East & Africa Calcium Channel Blockers Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 60. Middle East & Africa Calcium Channel Blockers Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 61. Middle East & Africa Calcium Channel Blockers Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 62. Middle East & Africa Calcium Channel Blockers Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 63. Middle East & Africa Calcium Channel Blockers Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 64. Middle East & Africa Calcium Channel Blockers Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 65. Middle East & Africa Calcium Channel Blockers Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 66. Middle East & Africa Calcium Channel Blockers Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 67. Global Calcium Channel Blockers Market Share Analysis, by Company, 2022